Not yet recruitingPhase 2NCT05202288
Impact of Delay Between Administration of Inmazeb Administration and Vaccination by Ervebo on Vaccine Immune Response on Healthy Volunteers
Studying Ebola hemorrhagic fever
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- ANRS, Emerging Infectious Diseases
- Principal Investigator
- Marie JASPARD, PHDCORAL
- Intervention
- Ervebo(biological)
- Enrollment
- 132 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2027 – 2027
Collaborators
University of Bordeaux · Institut National de la Santé Et de la Recherche Médicale, France · Clinical and Operational Research Alliance (CORAL) · Institut Pasteur · Regeneron Pharmaceuticals · MSD France · Alliance for International Medical Action · Centre de Recherche et de Formation en Infectiologie de Guinée (CERFIG) · PACCI Program
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05202288 on ClinicalTrials.govOther trials for Ebola hemorrhagic fever
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE4NCT05992480REVIVE (Response to the Ebola Virus Vaccine)Tulane University
- ACTIVE NOT RECRUITINGPHASE2NCT06803342A Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Sudan Ebolavirus Vaccine in Healthy AdultsAlbert B. Sabin Vaccine Institute
- RECRUITINGPHASE3NCT06126822Safety and Immunogenicity of Ervebo® and Zabdeno® Booster Vaccines Against Ebola Virus Following Previous Vaccination with the Zabdeno/Mvabea® or Ervebo® Vaccine Schedules in DRCInstitute of Tropical Medicine, Belgium
- ACTIVE NOT RECRUITINGPHASE2NCT06100913Immunology of Ebola VaccineEmory University